Review article: recent insights into clinical decision‐making in severe alcoholic hepatitis

Dunne, Philip D.; Forrest, Ewan

doi:10.1111/apt.14144

Cited by 1 publication

(1 citation statement)

References 75 publications

(84 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It uses age, serum bilirubin, blood urea nitrogen, PT ratio and the peripheral white cell count as variables, with a score of <9 being associated with an extremely poor mortality [33]. Research has shown that GAHS ≥ 9 may benefit from corticosteroid treatment, whereas those with a GAHS < 9 are unlikely to benefit from such treatment even if the DF is ≥32 [34,35]. One report suggests that ABIC, GAHS and MELD could be superior to the DF score [33].…”

Section: Glasgow Alcoholic Hepatitis Score (Gahs)mentioning

confidence: 99%

Emerging Noninvasive Biomarkers, and Medical Management Strategies for Alcoholic Hepatitis: Present Understanding and Scope

Gala

Vatsalya

2020

Cells

View full text Add to dashboard Cite

Alcohol use disorder is associated with a wide array of hepatic pathologies ranging from steatosis to alcoholic-related cirrhosis (AC), alcoholic hepatitis (AH), or hepatocellular carcinoma (HCC). Biomarkers are categorized into two main categories: biomarkers associated with alcohol consumption and biomarkers of alcoholic liver disease (ALD). No ideal biomarker has been identified to quantify the degree of hepatocyte death or severity of AH, even though numerous biomarkers have been associated with AH. This review provides information of some of the novel and latest biomarkers that are being investigated and have shown a substantial association with the degree and severity of liver injury and inflammation. Importantly, they can be measured noninvasively. In this manuscript, we consolidate the present understanding and prospects of these biomarkers; and their application in assessing the severity and progression of the alcoholic liver disease (ALD). We also review current and upcoming management options for AH.

show abstract

Section: Glasgow Alcoholic Hepatitis Score (Gahs)mentioning

confidence: 99%

Emerging Noninvasive Biomarkers, and Medical Management Strategies for Alcoholic Hepatitis: Present Understanding and Scope

Gala

Vatsalya

2020

Cells

View full text Add to dashboard Cite

show abstract

Review article: recent insights into clinical decision‐making in severe alcoholic hepatitis

Abstract: Recent studies have helped to define patients who may benefit from corticosteroid treatment. However, there remains a need for more accurate scores of prognosis and treatment response, and a clear need for alternative treatments for those patients not responding to corticosteroid therapy.

Cited by 1 publication

References 75 publications

Emerging Noninvasive Biomarkers, and Medical Management Strategies for Alcoholic Hepatitis: Present Understanding and Scope

Emerging Noninvasive Biomarkers, and Medical Management Strategies for Alcoholic Hepatitis: Present Understanding and Scope

Contact Info

Product

Resources

About